title: [What is the real importance of evaluating the expression of c-erbB-2 (HER-2/neu) in carcinoma of the breast and prostate? (A short review)].
abstract: This minireview covers the key data on biology and clinical implications of the c-erbB-2 oncogene in breast and prostate cancer. The aim was to provide basic information to practically oriented pathologists in order to make a reasonable application of methods for c-erbB-2 overexpression or amplification analysis. The clinical interpretation of c-erbB-2 abnormalities should reflect the complexity of c-erbB-2 mediated regulatory pathway and explain why tumours with overexpression/amplification of c-erbB-2 very often do not respond to therapy using Herceptin.
authors.affiliation: Ustav patologie LF UP a FN Olomouc & Laborator molekulární patologie LF UP, Univerzita Palackého, Olomouc. kolarz@tunw.upol.cz
authors.forename: Z
authors.initials: Z
authors.lastname: Kolár
authors.forename: J
authors.initials: J
authors.lastname: Dvorácková
authors.forename: P
authors.initials: P
authors.lastname: Plevová
authors.forename: V
authors.initials: V
authors.lastname: Student
authors.forename: M
authors.initials: M
authors.lastname: Hajdúch
authors.forename: R
authors.initials: R
authors.lastname: Trojanec
authors.forename: K
authors.initials: K
authors.lastname: Spacková
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D002277:Carcinoma / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab